Bioinformatics, Disease, Drug Development and Workshop

Big data – charting a new path to drug discovery and development

Drug Discovery World

JULY 11, 2023

In addition, the vast complexity of human disease often means we need a better understanding of all the variables involved in a specific process. These different fundamental approaches (rules-based versus pattern recognition) to building these systems provide multiple opportunities to interject them into disease diagnostics and treatments.

Science

Science Drugs FDA Engineering

Article FDA Thank You Leaders at FDA share highlights and updates for drugs and biologics at RAPS Convergence

Agency IQ

OCTOBER 12, 2023

Joneckis said that CBER has “some limited uses that we have seen in external submissions, mostly in the bioinformatics area,” but not as many as CDER. Regarding artificial intelligence (AI), an important topic at RAPS Convergence, the two centers discussed external and internal use cases.

FDA

FDA Clinical Trials International Drugs

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

NOVEMBER 15, 2022

It has made its way into almost every aspect of drug discovery, whether it’s exploring basic biology, modelling diseases, identifying and validating targets, or performing drug screens. . Synthetic libraries for antibody drug discovery .

DNA

DNA Engineering Drugs Vaccine

Drug Discovery Digest

Big data – charting a new path to drug discovery and development

Article FDA Thank You Leaders at FDA share highlights and updates for drugs and biologics at RAPS Convergence

Synthetic biology tools advancing and accelerating drug discovery efforts

Stay Connected